Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept fourth quarter revenue decreases to $0.1 million

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

XBiotech to enter biosimilar business

XBiotech to enter biosimilar business

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

Dyax fourth quarter total revenues increase to $16.0 million

Dyax fourth quarter total revenues increase to $16.0 million

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Glimmer of hope for imatinib-resistant GIST

Glimmer of hope for imatinib-resistant GIST

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Scientists produce monoclonal antibody in tobacco plants that neutralizes rabies viruses

Scientists produce monoclonal antibody in tobacco plants that neutralizes rabies viruses

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Teva terminates collaboration with CureTech

Teva terminates collaboration with CureTech

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

FDA accepts Genzyme’s LEMTRADA sBLA for review

FDA accepts Genzyme’s LEMTRADA sBLA for review

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.